Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. ITeos Therapeutics Inc shares valued at $38,635 were purchased by Gall Matthew on Nov 19 ’24. At $7.73 per share, Gall Matthew acquired 5,000 shares. The insider’s holdings grew to 65,429 shares worth approximately $0.52 million following the completion of this transaction.
As published in their initiating research note from Wells Fargo on August 13, 2024, ITeos Therapeutics Inc [ITOS] has been an Overweight and the price target has been revised to $31. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early May. As of October 08, 2020, Robert W. Baird has initiated its “an Outperform” rating for ITOS. Earlier on August 18, 2020, Wedbush initiated its rating. Their recommendation was “an Outperform” for ITOS stock.
Analyzing ITOS Stock Performance
During the last five days, there has been a drop of approximately -6.44%. Over the course of the year, ITeos Therapeutics Inc shares have dropped approximately -27.03%. Shares of the company reached a 52-week high of $18.75 on 05/10/24 and a 52-week low of $7.54 on 11/21/24. A 50-day SMA is recorded $9.00, while a 200-day SMA reached $12.96. Nevertheless, trading volume fell to 0.64 million shares from 0.36 million shares the previous day.
Support And Resistance Levels for ITeos Therapeutics Inc (ITOS)
According to the 24-hour chart, there is a support level at 7.88, which, if violated, would cause prices to drop to 7.77. In the upper region, resistance lies at 8.18. The next price resistance is at 8.37. RSI (Relative Strength Index) is 36.17 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.03, which suggests the price will decrease in the coming days. Percent R is at 62.18%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
